2023-05-30 10:16:36 ET
- Can-Fite BioPharma ( NYSE: CANF ) announced the publication of a study titled "Effects of Namodenoson on Pancreatic Carcinoma: Preclinical Evidence" in the Journal of Clinical Oncology supplement of the 2023 ASCO Annual Meeting Proceedings.
- The pre-clinical study demonstrated that Namodenoson significantly inhibited the growth of pancreatic carcinoma as a stand-alone treatment and in combination with gemcitabine, the leading chemotherapy for pancreatic cancer.
- ( CANF ) is trading 11% higher .
- The study also revealed a dose-dependent inhibition of pancreatic cancer cell growth when exposed to Namodenoson. The combined treatment with Namodenoson plus gemcitabine had an additive inhibitory effect.
- Can-Fite plans to initiate an open-label Phase 2a exploratory trial to assess the efficacy and safety of Namodenoson in treating patients with pancreatic cancer who have received at least one previous systemic therapy.
- Safety and efficacy endpoints, including objective response, progression-free survival, duration of response, disease control, and overall survival, will be monitored in the study.
- Press release
For further details see:
Can-Fite's Namodenoson shows promising results in preclinical study on pancreatic carcinoma, shares rise 11%